Employees 2013: 112,128
Employees 2012: 111,974
% Change: +0.14
Revenues 2013: $45.08 billion
Revenues per employees 2013: $402,022

Sanofi ($SNY) CEO Chris Viehbacher tried, and failed, to slash employee numbers in 2013. The third largest pharma company by number of employees, Sanofi planned to lay off 2,500 employees in 2012. Rumor spread and unions, particularly in France, spoke out in outrage. Sanofi reeled in the layoff number to 800 but still faced backlash from the French government.

The company is headquartered in Paris, but it finds its own backyard to be a drag on the R&D front. Viehbacher defended the company's position on French layoffs with the fact that the Toulouse, France-based R&D department had not come out with a significant drug in 20 years. Out of 12 drug launches from 2013 through 2015, only two were being developed in France, a Sanofi spokeswoman said in a Reuters article.

The slowdown of research in France and the 2.87% decrease in revenue from 2012 to 2013 added pressure on the company to restructure. With a less-than-stellar year behind it, Viehbacher went into 2014 with optimism for improvements, and by the end of the second quarter, Sanofi shares were up 4%.

For more:
Special Reports: Sanofi - The top 10 largest pharma layoffs in 2013 | Sanofi - Top 10 pharma companies by employees
After tougher than expected 2013, Sanofi anticipates patent-cliff freedom


Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.